Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NFIB dependent and independent mechanisms of metastasis in small cell lung cancer

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE228334 | GEO | 2023/11/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

NFIB dependent and independent mechanisms of metastasis in small cell lung cancer [ATAC-seq]

Project description:Molecular characterization of lung tumors and liver metastases from SCLC mouse models with and without Nfib knockout. We performed gene expression profiling analysis using data obtained from ATAC-seq of 7 mouse SCLC cell lines.

2023-11-07 | GSE227669 | GEO

NFIB dependent and independent mechanisms of metastasis in small cell lung cancer [RNA-seq]

2023-11-07 | GSE228333 | GEO

NFIB dependent and independent mechanisms of metastasis in small cell lung cancer

Project description:NFIB dependent and independent mechanisms of metastasis in small cell lung cancer

| PRJNA949286 | ENA

NFIB dependent and independent mechanisms of metastasis in small cell lung cancer [ATAC-seq]

Project description:NFIB dependent and independent mechanisms of metastasis in small cell lung cancer [ATAC-seq]

| PRJNA946306 | ENA

NFIB dependent and independent mechanisms of metastasis in small cell lung cancer [RNA-seq]

Project description:NFIB dependent and independent mechanisms of metastasis in small cell lung cancer [RNA-seq]

| PRJNA949350 | ENA

Mechanisms of small cell lung cancer metastasis.

Project description:Metastasis is a major cause of morbidity and mortality in cancer patients. However, the molecular and cellular mechanisms underlying the ability of cancer cells to metastasize remain relatively poorly understood. Among all solid tumors, small cell lung cancer (SCLC) has remarkable metastatic proclivity, with a majority of patients diagnosed with metastatic disease. Our understanding of SCLC metastasis has been hampered for many years by the paucity of material from primary tumors and metastases, as well as the lack of faithful pre-clinical models. Here, we review recent advances that are helping circumvent these limitations. These advances include methods that employ circulating tumor cells from the blood of SCLC patients and the development of diverse genetically engineered mouse models of metastatic SCLC. New insights into the cellular mechanisms of SCLC metastasis include observations of cell fate changes associated with increased metastatic ability. Ongoing studies on cell migration and organ tropism promise to expand our understanding of SCLC metastasis. Ultimately, a better molecular understanding of metastatic phenotypes may be translated into new therapeutic options to limit metastatic spread and treat metastatic SCLC.

| S-EPMC7799359 | biostudies-literature

Antagonizing miR-128 abrogates chemoresistance-associated metastasis and is therapeutic in non-small cell lung cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2015-04-10 | E-GEOD-67729 | biostudies-arrayexpress

DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.

Project description:Expression of the tumor suppressor deleted in liver cancer-1 (DLC-1) is lost in non-small cell lung (NSCLC) and other human carcinomas, and ectopic DLC-1 expression dramatically reduces proliferation and tumorigenicity. DLC-1 is a multi-domain protein that includes a Rho GTPase activating protein (RhoGAP) domain which has been hypothesized to be the basis of its tumor suppressive actions. To address the importance of the RhoGAP function of DLC-1 in tumor suppression, we performed biochemical and biological studies evaluating DLC-1 in NSCLC. Full-length DLC-1 exhibited strong GAP activity for RhoA as well as RhoB and RhoC, but only very limited activity for Cdc42 in vitro. In contrast, the isolated RhoGAP domain showed 5- to 20-fold enhanced activity for RhoA, RhoB, RhoC, and Cdc42. DLC-1 protein expression was absent in six of nine NSCLC cell lines. Restoration of DLC-1 expression in DLC-1-deficient NSCLC cell lines reduced RhoA activity, and experiments with a RhoA biosensor demonstrated that DLC-1 dramatically reduces RhoA activity at the leading edge of cellular protrusions. Furthermore, DLC-1 expression in NSCLC cell lines impaired both anchorage-dependent and -independent growth, as well as invasion in vitro. Surprisingly, we found that the anti-tumor activity of DLC-1 was due to both RhoGAP-dependent and -independent activities. Unlike the rat homologue p122RhoGAP, DLC-1 was not capable of activating the phospholipid hydrolysis activity of phospholipase C-delta1. Combined, these studies provide information on the mechanism of DLC-1 function and regulation, and further support the role of DLC-1 tumor suppression in NSCLC.

| S-EPMC2679972 | biostudies-literature

CRTC1-MAML2 fusion oncogene-induced transcriptional program is regulated by CREB-dependent and -independent mechanisms

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-07-25 | E-GEOD-59795 | biostudies-arrayexpress

Lung cancer bone metastasis

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-09-16 | GSE225212 | GEO